Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term POSTMENOPAUSAL WOMEN. Found 18 abstracts

Jordan VC. A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention. Cancer Research. 2009 Feb;69(4):1243-54.
McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Kaaks R, Rinaldi S, Helzlsouer KJ. Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. International journal of cancer. 2009 Aug;125(3):674-9.   PMCID: PMC2706295
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. Journal of Clinical Oncology. 2009 Jul;27(19):3235-58.   PMCID: PMC 2716943
Chu QS, Cianfrocca ME, Goldstein LJ, Gale M, Murray N, Loftiss J, Arya N, Koch KM, Pandite L, Fleming RA, Paul E, Rowinsky EK. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clinical Cancer Research. 2008 Jul;14(14):4484-90.
Harvey JA, Santen RJ, Petroni GR, Bovbjerg VE, Smolkin ME, Sheriff FS, Russo J. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause-the Journal of the North American Menopause Society. 2008 Jan;15(1):67-73.
Baer HJ, Colditz GA, Willett WC, Dorgan JF. Adiposity and sex hormones in girls. Cancer Epidemiology Biomarkers & Prevention. 2007 Sep;16(9):1880-8.
Cui XH, Dai Q, Tseng M, Shu XO, Gao YT, Zheng W. Dietary patterns and breast cancer risk in the Shanghai breast cancer study. Cancer Epidemiology Biomarkers & Prevention. 2007 Jul;16(7):1443-8.
Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2007 Nov;107(2):260-5.
Janz NK, Mujahid M, Chung LK, Lantz PM, Hawley ST, Morrow M, Schwartz K, Katz SJ. Symptom experience and quality of life of women following breast cancer treatment. Journal of Womens Health. 2007 Nov;16(9):1348-61.
Jordan VC. Opinion - Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature Reviews Cancer. 2007 Jan;7(1):46-53.
Jordan VC. Successful translation research with selective oestrogen receptor modulators to treat and prevent breast cancer. Geburtshilfe Und Frauenheilkunde. 2007 May;67(5):443-50.
Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007 Jan;72(1):7-25.
Jordan VC, Lewis-Wambi J, Kim H, Cunliffe H, Ariazi E, Sharma CG, Shupp HA, Swaby R. Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast. 2007 Dec;16:S105-S113.
Kotsopoulos J, Ghadirian P, El-Sohemy A, Lynch HT, Snyder C, Daly M, Domchek S, Randall S, Karlan B, Zhang P, Zhang SY, Sun P, Narod SA. The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers. Cancer Epidemiology Biomarkers & Prevention. 2007 May;16(5):912-6.
Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. International Journal of Oncology. 2007 Feb;30(2):509-20.
Ariazi EA, Lewis-Wambi JS, Gill SD, Pyle JR, Ariazi JL, Kim HR, Sharma CG, Cordera F, Shupp HA, Li TY, Jordan VC. Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant. Journal of Steroid Biochemistry and Molecular Biology. 2006 Dec;102(1-5):128-38.
Chatterton RT, Zujewski J, Mateo ET, Eng-Wong J, Jordan VC. Effect of raloxifene on salivary sex steroid concentrations in premenopausal women. Journal of Endocrinology. 2006 Dec;191(3):599-604.
Jordan VC. Optimising endocrine approaches for the chemoprevention of breast cancer - Beyond the Study of Tamoxifen and Raloxifene (STAR) Trial. European Journal of Cancer. 2006 Nov;42(17):2909-13.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term POSTMENOPAUSAL WOMEN

POSTMENOPAUSAL WOMEN RANDOMIZED-TRIAL BOWEL PROJECT P-1 SURGICAL ADJUVANT BREAST ATHYMIC MICE MAMMARY-CARCINOMA MODEL tamoxifen breast cancer ESTROGEN-RECEPTOR THERAPY RISK RALOXIFENE TAMOXIFEN-STIMULATED GROWTH aromatase inhibitors AROMATASE INHIBITOR LETROZOLE 474 ICI 46 ANTIESTROGENS MORTALITY TAMOXIFEN TAMOXIFEN RESISTANCE ADJUVANT TREATMENT raloxifene ITALIAN RANDOMIZED-TRIAL NEGATIVE MAMMARY-TUMORS COMBINATION DEVELOPING BREAST-CANCER BODY-IMAGE INDUCED APOPTOSIS BREAST-CANCER PREVENTION TRIAL BREAST-CANCER RISK prevention REPRODUCTIVE HORMONES EPIDERMAL-GROWTH-FACTOR PREVENTION 4-hydroxyandrostenedione SERM MONOCLONAL-ANTIBODY ENDOCRINE PARENCHYMAL DENSITY BMI body weight IMPACT CARBOPLATIN AROMATASE INHIBITORS POPULATION REPRODUCIBILITY MAMMOGRAPHIC DENSITY RANDOMIZED CLINICAL-TRIAL ANTIOXIDANT TUMOR-GROWTH PREMENOPAUSAL CHEMOTHERAPY PHYSICAL-ACTIVITY fulvestrant FIRST-LINE THERAPY CANCER RISK STAR DIETARY INTERVENTION ovarian cancer RESTORE ATTENTION CYP2D6 GENOTYPE ANTI-TUMOUR AGENT gene array analysis BONE-MINERAL ADJUVANT BREAST ADJUVANT LONG-TERM VALIDITY CANCER TISSUE-CULTURE ADOLESCENT GIRLS SURFACE EPITHELIAL-CELLS OBESITY FIRST-LINE CONSUMPTION LUTEINIZING-HORMONE OUTCOMES METASTATIC BREAST-CANCER ESTROGEN-RECEPTOR MODULATION METASTASIS OVERWEIGHT POLYCYSTIC-OVARY-SYNDROME 474 TAMOXIFEN ICI 46 INHIBITION FEMALE PUBERTY PLUS PROGESTIN antihormone resistance POLYMORPHISMS PACLITAXEL histology HEALTH EUROPEAN-ORGANIZATION PROGESTERONE chemotherapy ENDOMETRIAL CANCER TYROSINE KINASE MAMMARY-GLAND neu CAFFEINE CONTINUING OUTCOMES RELEVANT QUALITY-OF-LIFE TREATMENT survival hormone therapy PLASMA DENSITY-LIPOPROTEIN CHOLESTEROL ADVANCED BREAST-CANCER BONE-MINERAL DENSITY HORMONES ER-ALPHA EXPRESSION BODY-FAT DISTRIBUTION mammography AROMATASE INHIBITOR LOW-DOSE TAMOXIFEN CLINICAL-TRIALS TEA breast ANDROGEN RECEPTOR MODULATORS GENE-TRANSCRIPTION LONG-TERM TAMOXIFEN AROMATASE-ACTIVITY RANDOMIZED CONTROLLED-TRIAL GROWTH-FACTOR RECEPTOR SURGICAL BODY-MASS INDEX HER2 LETROZOLE PREMENOPAUSAL WOMEN FOOD-FREQUENCY QUESTIONNAIRE ovarian cancer follicle stimulating hormone (FSH)-gonadotropins-epidemiology-cohort study HOT FLASHES MCF-7 CELLS DOUBLE-BLIND LH PROLIFERATION INHIBITOR HIGH-RISK REPLACEMENT THERAPY DENSITY 1ST-LINE CROSS-TALK COHORT YOUNGER WOMEN SURVIVORS FACTOR-RECEPTOR estradiol breast cancer-tamoxifen-raloxifene-fulvestrant DICS ANTI-ESTROGENS
Last updated on Wednesday, July 08, 2020